NeuMedics is developing proprietary eyedrops to treat inflammatory eye diseases including Diabetic Macular Edema, Trauma and Dry Eye all unmet medical needs
NeuMedics has developed anti-inflammatory compounds that also have anti VEGF properties. They are designed for topical delivery to the eye to treat Diabetic Macular Edema (DME). DME is the leading cause of blindness for 2.5 million diabetic patients in U.S.; 75,000 new cases each year in U.S. Patients suffering from this disease are limited to expensive Biologic drugs or steroids and require frequent direct injections into the eye.